| (Values in U.S. Thousands) | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 |
| Sales | 70 | 3,000 | 2,940 | 3,340 | 2,790 |
| Sales Growth | -97.67% | +2.04% | -11.98% | +19.71% | -12.54% |
| Net Income | 10,320 | -4,750 | 420 | 370 | -1,170 |
| Net Income Growth | +317.26% | -1,230.95% | +13.51% | +131.62% | -320.75% |
Guardion Health Sciences Inc (GHSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Guardion Health Sciences Inc. is an ocular health sciences company. It develops, formulates and distributes condition-specific medical foods supported by evidence-based protocols, with an initial medical food product which addresses a depleted macular protective pigment. The company also developed a proprietary medical device, the MapcatSF(R), which accurately measures the macular pigment density. Guardion Health Sciences Inc. is based in San Diego, United States.
Fiscal Year End Date: 12/31